In a report released on October 28, Brandon Couillard from Jefferies maintained a Buy rating on Bio-Rad Laboratories (BIO - Research Report), with a price target of $600.00. The companys shares closed ...
Today, we will review the fourth quarter and full year 2025 financial results and provide an update on key business trends ...
Throughout the last three months, 5 analysts have evaluated Bio-Rad Laboratories (NYSE:BIO), offering a diverse set of opinions from bullish to bearish. The following table summarizes their recent ...
In a report released today, Conor McNamara from RBC Capital maintained a Buy rating on Bio-Rad Laboratories (BIO – Research Report), with a price target of $401.00. The company’s shares closed ...
Bio-Rad Laboratories (BIO) has been under pressure recently, with the stock showing negative returns over the past week, month and past 3 months, as well as over 1 year and multi year periods. At the ...
Hosted on MSN
Bio-Rad Labs A Sees IBD RS Rating Rise To 72
On Wednesday, Bio-Rad Labs ABIO got an upgrade to its Relative Strength (RS) Rating, from 69 to 72. Please watch the video at Investors.com - Find Top Growth Stocks With The IBD Screen Of The Day How ...
We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Bio-Rad Laboratories, Inc. stands tenth on our list and is currently making waves for launching a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results